Regeneron Tops Q1 Estimates But Lowers Margin Guidance, Sending Stock Lower

2
Comment
Favorite

Regeneron Tops Q1 Estimates But Lowers Margin Guidance, Sending Stock Lower

Dow Jones2023-05-04

Regeneron Pharmaceuticals Inc. 's stock $(REGN)$ slid 4% premarket Thursday, after the company topped estimates for first-quarter earnings but lowered margin guidance for 2023.

The Tarrytown, N.Y.-based drug company had net income of $818 million, or $7.17 a share, for the quarter, down from $974 million, or $8.61 a share, in the year-earlier period. Adjusted EPS came to $10.09, ahead of the $9.52 FactSet consensus.

Revenue rose 7% to $3.162 billion from $2.965 billion, also ahead of the $3.000 billion FactSet consensus. U.S. sales of the company's Eylea treatment for age-related macular degeneration fell 6% to $1.43 billion, below the FactSet consensus of $1.59 billion.

The company lowered its 2023 gross margin guidance to a range of 87% to 89% from 88% to 90% previously. The stock has gained 11% in the year to date, while the S&P 500 has gained 6.5%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2332116655?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-05-04 20:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2332116655","market":"us","top_or_hot":-1,"title":"Regeneron Tops Q1 Estimates But Lowers Margin Guidance, Sending Stock Lower","media":"Dow Jones","content":"<html><head></head><body><p>Regeneron Pharmaceuticals Inc. &#39;s stock <a href=\"https://laohu8.com/S/REGN\">$(REGN)$</a> slid 4% premarket Thursday, after the company topped estimates for first-quarter earnings but lowered margin guidance for 2023. </p><p>The Tarrytown, N.Y.-based drug company had net income of $818 million, or $7.17 a share, for the quarter, down from $974 million, or $8.61 a share, in the year-earlier period. Adjusted EPS came to $10.09, ahead of the $9.52 FactSet consensus. </p><p>Revenue rose 7% to $3.162 billion from $2.965 billion, also ahead of the $3.000 billion FactSet consensus. U.S. sales of the company&#39;s Eylea treatment for age-related macular degeneration fell 6% to $1.43 billion, below the FactSet consensus of $1.59 billion. </p><p>The company lowered its 2023 gross margin guidance to a range of 87% to 89% from 88% to 90% previously. The stock has gained 11% in the year to date, while the S&amp;P 500 has gained 6.5%.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron Tops Q1 Estimates But Lowers Margin Guidance, Sending Stock Lower</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron Tops Q1 Estimates But Lowers Margin Guidance, Sending Stock Lower\n</h2>\n\n<h4 class=\"meta\">\n\n2023-05-04 20:32 北京时间&nbsp;&nbsp;&nbsp;<strong>Dow Jones</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Regeneron Pharmaceuticals Inc. 's stock $(REGN)$ slid 4% premarket Thursday, after the company topped estimates for first-quarter earnings but lowered margin guidance for 2023. The Tarrytown, N.Y.-...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"REGN","symbol_name":"再生元制药公司","start_time":0,"source_url":"","article_id":"2332116655","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2332116655","pubTimestamp":1683203565,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Regeneron Pharmaceuticals Inc. 's stock $(REGN)$ slid 4% premarket Thursday, after the company toppe","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"REGN":"再生元制药公司"},"translate_title":"Regeneron高于第一季度预期，但下调了利润率指引，导致股价走低","themeId":"ec9f6f0df2b6498587e7f5318b2eff2b","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":0.9},"content_text":"Regeneron Pharmaceuticals Inc. 's stock $(REGN)$ slid 4% premarket Thursday, after the company topped estimates for first-quarter earnings but lowered margin guidance for 2023. The Tarrytown, N.Y.-based drug company had net income of $818 million, or $7.17 a share, for the quarter, down from $974 million, or $8.61 a share, in the year-earlier period. Adjusted EPS came to $10.09, ahead of the $9.52 FactSet consensus. Revenue rose 7% to $3.162 billion from $2.965 billion, also ahead of the $3.000 billion FactSet consensus. U.S. sales of the company's Eylea treatment for age-related macular degeneration fell 6% to $1.43 billion, below the FactSet consensus of $1.59 billion. The company lowered its 2023 gross margin guidance to a range of 87% to 89% from 88% to 90% previously. The stock has gained 11% in the year to date, while the S&P 500 has gained 6.5%.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}